Age is the most relevant risk factor for breast cancer, and almost half of breast cancer cases in the US are diagnosed in women older than 70 years.1 However, elderly adults are a heterogeneous population characterized by considerable differences in biological age, function, burden of comorbidities, cognition, nutritional status, psychosocial problems, and social support. Moreover, elderly adults are frequently excluded from therapeutic clinical trials, which explains the substantial lack of validated, empirical evidence to guide management of breast cancer in this specific age group. These issues pose a challenge for practitioners, especially in the context of curative treatment decisions. Comorbidities may substantially influence therapeutic decisions in elderly patients with breast cancer in view of competing risks of death, reduced functional reserve, impaired organ function, and higher risk of toxic effects.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Battisti NML, McCartney A, Biganzoli L. The Conundrum of the Association of Chemotherapy With Survival Outcomes Among Elderly Patients With Curable Luminal Breast Cancer. JAMA Oncol. Published online July 16, 2020. doi:10.1001/jamaoncol.2020.2194
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: